Crossmark

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Crossref DOI link: https://doi.org/10.1136/jitc-2022-005701

Published Online: 2023-02-20

Published Print: 2023-02

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Song, Fengmei https://orcid.org/0000-0003-1123-9407
Hu, Yongxian

Zhang, Yanlei

Zhang, Mingming

Yang, Tingting

Wu, Wenjun

Huang, Simao

Xu, Huijun

Chang, Alex H

Huang, He https://orcid.org/0000-0002-2723-1621
Wei, Guoqing
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04532268 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
https://doi.org/10.1136/jitc-2022-005701
Funding

Funding for this research was provided by:

Key projects of the National Natural Science Foundation of China (81730008)

Key projects of the National Natural Science Foundation of China (82130003)

key R & D Program of Zhejiang Province (2018C03016-2)

key R & D Program of Zhejiang Province (2019C03016)

General Project of the National Natural Science Foundation of China (81870153)
License Information

License valid from 2023-02-20